Tradestie Institutional Equity Comparison Engine

HRMY vs AQST โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

HRMY Overall Edge

HRMY Captures Institutional Edge (4โ€“0 Pillars ยท 10โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harmony Biosciences Holdings, Inc. Common Stock (HRMY) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, HRMY trades at 5.4x Forward P/E with 22.2% operating margin (+12.3% YoY revenue) versus AQST at N/M Forward P/E and -114.1% operating margin (-41.0% YoY). In options structure, HRMY sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro) against AQST sits in BREAKDOWN (64th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner HRMY
HRMY 5.4x vs AQST N/M Fwd P/E
Growth & Margin Winner HRMY
Op Margin 22.2% vs -114.1% ยท YoY +12.3% vs -41.0%
Momentum & Technical Winner HRMY
1Y -2.2% vs -40.6% ยท 52W Pos 38% vs 14%
Options & Structure Winner HRMY
CONSOLIDATION (11th %ile IV) vs BREAKDOWN (64th %ile IV)
HRMY NASDAQ
Harmony Biosciences Holdings, Inc. Common Stock
Pharmaceutical Preparations
$32.59
-1.18% 1D
Market Cap $1.9B
1M Return -9.55%
1Y Return -2.16%
Forward P/E 5.4x
Unified AI Score
67.1 / 100 BUY
Tech 80.0 Fund 74.0 Flow 70.0 Mom 70.0
AQST NASDAQ
Aquestive Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$3.46
-6.61% 1D
Market Cap $465.7M
1M Return -16.22%
1Y Return -40.65%
Forward P/E N/M
Unified AI Score
62.9 / 100 BUY
Tech 54.0 Fund 68.0 Flow 68.0 Mom 60.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: HRMY -2.16% AQST -40.65% Spread: +38.49 pp (HRMY Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period HRMY Revenue AQST Revenue HRMY Op. Margin AQST Op. Margin Margin Edge
FY2018 N/A $70M N/A -72.6% AQST
FY2019 $10M $50M -2433.8% -100.1% AQST
FY2020 $160M $50M 10.6% -93.6% HRMY
FY2021 $310M $50M 28.7% -68.2% HRMY
FY2022 $440M $50M 27.4% -88.2% HRMY
FY2023 $580M $50M 33.0% -29.9% HRMY
FY2024 $710M $60M 26.7% -53.5% HRMY
FY2025 $870M $40M 24.0% -159.5% HRMY

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: HRMY (10) vs AQST (0)
Institutional Metric HRMY AQST Criterion Row Winner
Market Capitalization Scale $1.9B $465.7M Larger Scale HRMY
Trailing P/E Ratio Valuation 10.9x N/M Lower Multiple HRMY
Forward P/E Ratio Valuation 5.4x N/M Lower Multiple HRMY
Revenue Growth (YoY) Growth +12.3% -41.0% Higher Growth HRMY
Operating Margin (TTM) Profitability 22.2% -114.1% Higher Margin HRMY
Net Profit Margin Profitability 18.1% -162.3% Higher Margin HRMY
Return on Equity (ROE) Capital Efficiency 18.7% 0.0% Higher ROE HRMY
52-Week Range Position Momentum 38% ($26โ€“$43) 14% ($3โ€“$7) Stronger Trend HRMY
Beta / 30D Volatility Risk Regime 0.55ฮฒ ยท 38% Vol 0.89ฮฒ ยท 56% Vol Lower Realized Risk HRMY
Unified Institutional Score Composite Signal 67.1 / 100 (BUY) 62.9 / 100 (BUY) Higher Composite HRMY

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full HRMY vs AQST Buy Guide
HRMY CONSOLIDATION
114d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 11th %ile
IV Regime Compressed (<25th %ile)
Live HRMY Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
AQST BREAKDOWN
61d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 64th %ile
IV Regime Elevated (60thโ€“80th %ile)
Live AQST Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither HRMY nor AQST registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.